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PhosphorylationHypertension represents a complex, multifactorial disease and contributes to the major causes of morbidity
and mortality in industrialized countries: ischemic and hypertensive heart disease, stroke, peripheral
atherosclerosis and renal failure. Current pharmacological therapy of essential hypertension focuses on the
regulation of vascular resistance by inhibition of hormones such as catecholamines and angiotensin II,
blocking them from receptor activation. Interaction of G-protein coupled receptor kinases (GRKs) and
regulator of G-protein signaling (RGS) proteins with activated G-protein coupled receptors (GPCRs) effect
the phosphorylation state of the receptor leading to desensitization and can profoundly impair signaling.
Defects in GPCR regulation via these modulators have severe consequences affecting GPCR-stimulated
biological responses in pathological situations such as hypertension, since they ﬁne-tune and balance the
major transmitters of vessel constriction versus dilatation, thus representing valuable new targets for anti-
hypertensive therapeutic strategies. Elevated levels of GRKs are associated with human hypertensive disease
and are relevant modulators of blood pressure in animal models of hypertension. This implies therapeutic
perspective in a disease that has a prevalence of 65 million in the United States while being directly
correlated with occurrence of major adverse cardiac and vascular events. Therefore, therapeutic approaches
using the inhibition of GRKs to regulate GPCRs are intriguing novel targets for treatment of hypertension and
heart failure.ry for Vascular Biology and
f Medicine, Thomas Jefferson
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G-Protein coupled receptor (GPCR) kinases (GRKs) regulate vital pro-
cesses by controlling expression and function of seven-transmembrane
receptors such as adrenergic and angiotensin receptors [1]. These are
particularly important in widespread cardiovascular disease resulting
from hypertension, where the degree of constriction of blood vessels is
generated in part by elevated levels of agonists such as catecholamines
and angiotensin II [2]. Vascular smooth muscle (VSM) is a key player
contributing to the regulation of blood pressure by controlling the
diameter of blood vessels and thereby modulating peripheral resistance.
Because of the exponential relationship between diameter and resistance
(resistanceα1/r4), contraction of VSM has the potential to dramatically
increase blood pressure. The hypercontractile state of VSM is one
hallmark of essential hypertension. In turn, elevated blood pressure
requires the heart to adapt to accommodate higher systolic loads which
ultimately leads to ventricular hypertrophy and reduced myocardial
compliance [3,4].Since GPCRs expressed on VSM and endothelial cells are
responsible for maintaining the balance between constriction and
relaxation of vessels, their modulation has been a primary target
of therapeutic advances. Agonists binding to a GPCR trigger the
activation of heterotrimeric G-proteins that transduce the signal to
intracellular effector molecules [5]. Upon activation, the heterotri-
meric G-protein complex disassembles into Gα and Gβγ subunits.
There are four main classes of heterotrimeric G-proteins, described
based on the Gα component, and activation of different Gα subtypes
lead to diverse intracellular signaling cascades eliciting contractile
response by (i) activation of adenylyl cyclase (Gαs), (ii) phospholi-
pase C initiating Ca2+ release from intracellular stores (Gαq/11), (iii)
inhibition of adenylyl cyclase (Gαi), or (iv) Rho kinase (Gα12/13 and
Gαq/11), which inhibits the myosin light chain phosphatase (MLCP),
ﬁnally activating the myosin light chain (MLC) [6–8] and thereby
initiating vasoconstriction. This can lead to complex and conﬂicting
responses in the vasculature where catecholamines for instance are
acting as vasoconstricting agonists when binding to α-adrenergic
receptors in peripheral arteries but can likewise lead to vasodilation
when binding to β-adrenergic receptors activating the Gαs subunit
that stimulates cAMP formation and smooth muscle relaxation
(Fig. 1).
GPCRs are tightly regulated by a family of kinases, GRKs, that
upon activation phosphorylate the receptor, thereby increasing its
Fig. 1. Overview of GPCR signaling cascade resulting in vasodilation or vasoconstriction: Within the present reviewwe have outlined activation of GPCRs via a wide range of agonists,
leading to activation of adenylyl cyclase (AC) via Gαs as well as guanylate cyclase (GC), increased 2nd messenger concentrations ﬁnally leading to protein kinase A or G-mediated
vasodilation. Vasoconstrictory agents lead to activation of Gq and G12/13, which mediates smooth muscle contraction via Protein Kinase C (PKC) or Rho Kinase as well as increased
Ca2+, leading to inactivation of the myosin light chain kinase (MLCK) by dephosphorylation.
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coupling of that receptor to its Gα-protein [9]. This process is
termed desensitization and can occur as an immediate response to
agonist binding and with persistent stimulation can result in
receptor internalization and down-regulation thus attenuating
signaling [10]. It is believed to protect the receptive cell from
overstimulation but desensitization can be harmful in pathological
conditions such as heart failure, where desensitization of the β-
adrenergic receptor system marks the decline of ventricular
output.
GRKs form a family of seven mammalian members (GRK1–
GRK7), that share a similar basic structure with an N-terminus that
bears an RGS domain, a catalytic and a C-terminal domain [11].
Distinguishing variability occurs at the carboxy-terminal sequence
[12]. GRKs can be subdivided into three types: The GRK1-like retinal
opsin kinases, consisting of GRK1 and GRK7, known to be involved
in the pathophysiology of deleterious rhodopsin mutations that
underlie several inherited retinal disorders [10]. GRK2-like-
enzymes, including GRK2 and GRK3, act on a wide range of
GPCRs and were ﬁrst characterized in studies of the phosphoryla-
tion of agonist-occupied β2-adrenergic receptors, where GRK2 can
contribute to diseases such as heart failure [13]. Kinases of this
subtype share a carboxyl-terminal pleckstrin homology (PH)
domain, that mediates phosphoinositol-4,5-bisphosphonate (PIP2)
and G-Protein βγ-subunit speciﬁc regulation. Lastly, the GRK4-like
subfamily consists of GRK4, GRK5 and GRK6, which in contrast to the
other subtypes, selectively phosphorylate basic terminal amino acid
residues. GRK4 has been found to play an important role in regulating
the Dopamine D1 receptor within the renal proximal tubule, thus
controlling blood pressure [14]. Polymorphisms in the GRK4γ locus
can be linked to essential hypertension in patients who have
decreased D1 signaling and decreased adenylyl cyclase activity. The
distribution of 3 of the GRKs is limited. GRK1/GRK7 are mainly in the
ocular system whereas GRK4 is limited to the proximal tubule of the
kidney and testis. This suggests these GRKs may be successful
therapeutic targets because of their limited distribution and thus low
potential for side-effects. However, most of the over 1000 GPCRs of
the body seem to be regulated by only the four widely expressedisoforms: GRK2, GRK3, GRK5 and GRK6, and their downstream
arrestins, Arrestin-2 and Arrestin-3 (β-Arrestin-1 and β-Arrestin-2,
respectively).
Studies of GRKs in cardiovascular pathophysiology have mostly
been performed in cellular and animal models of heart disease, where
increased GRK levels are associated with hypertrophy and the
progression of heart failure [15,16]. This review will provide an
overview of the GPCR-mediated signaling regulation via GRKs as well
as RGS proteins, which share homologous regions with some GRKs, in
development and maintenance of high blood pressure. We will focus
on the pathophysiological role of GRKs taking into account recent
studies in genetically modiﬁed animals as well as a view of involve-
ment and regulation of GRKs in human cardiovascular disease. In the
current review, we focus on GRK2 and GRK5, as our focus is the role
VSM plays in blood pressure regulation. Another critical regulator of
renal GPCRs in hypertension, GRK4, is reviewed elsewhere (please
refer to review by PA Jose in this issue).
2. Adenylyl cyclase and phospholipase C in hypertension
Many of the earliest and consistent ﬁndings support the assump-
tion that hypertension is due in part to dysregulation and desensi-
tization of vasodilatory receptors. Mainly Gs-coupled receptors such
as β-adrenergic, histamine and dopamine D1-receptors impart vaso-
dilation and their alteration ultimately leads to decreased adenylyl
cyclase activity and cAMP formation. This was shown to impair VSM
relaxation and linked to hypertension in animal models such as the
spontaneously hypertensive heart failure (SHHF) rat [17]. Activity of
adenylyl cyclase has additionally been shown to be reduced in various
animal models of induced hypertension in response to Gs-coupled
receptor agonists [18]. In humans, isoproterenol-stimulated lympho-
cytes, isolated from borderline hypertensive subjects, were less
responsive and showed decreased adenylyl cyclase activity compared
to healthy subjects [19]. Interestingly, Gi, a major inhibitor of adenylyl
cyclase is also upregulated in VSM and myocardium of hypertensive
subjects in animal models as well as humans. Therefore, altered
adenylyl cyclase activity may be involved in the development and
maintenance of high blood pressure [20]. The potential therapeutic
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emerging novel compound selectively inhibiting speciﬁc adenylyl
cyclase isoforms in the heart, brain and possibly also the vasculature
[21].
The role of phospholipase C (PLC) in hypertension is reciprocal
to the one of adenylyl cyclase in that it is a mediator of pathways
transmitting vasoconstrictive signals. Downstream of PLC, increased
protein kinase C (PKC) and Ca2+ levels increase myosin light chain
kinase (MLCK) activity, which is balanced by phosphorylated MLC,
thus controlling constriction of smooth muscle in resistance vessels.
In hypertensive rats, protein levels of both PLC and PKC isoforms are
upregulated, suggesting augmented signaling via this pathway
through GPCRs, perhaps additionally responsible for elevated
blood pressure. Whether certain Gq-coupled constricting GPCRs
are not a target of GRKs or whether GRK phosphorylation of these
receptors promotes alternative signaling pathways remains to be
determined.
Additionally, signaling through constrictive GPCRs such as the
angiotensin II receptor also activates RhoA Kinase (ROCK) through
Gα12/13,[22,23] as well as Gαq/11 [24]via RhoGEFs (RhoGTPase
nucleotide exchange factors). RhoA as well as ROCK are increased in
animal models of hypertension, but also have a role in vascular
remodeling and smooth muscle cell proliferation [25] Selective
inhibition of ROCKs can normalize blood pressure as a result of
ameliorated vascular hypersensitivity [26]. How this pathway may be
regulated by GRKs warrants further investigation.3. Ion channels and hypertension
GPCR activation and desensitization via GRKs affect the balance of
ion channel activation in VSM. Vasoconstriction, in general, is
mediated by intracellular Ca2+, governing the contractile force and
maintenance of smooth muscle contraction. The open-probability of
the L-type calcium channel (LTCC), Ca2+ inﬂux and therefore the
intracellular Ca2+ concentration is inﬂuenced by GPCR signaling.
Angiotensin II, for instance, mediates vasoconstriction by increasing
intracellular Ca2+ by activation of IP3-sensitive Ca2+ stores. Further-
more, inhibition of voltage gated K+ channels by PKC leads to
decreased K+ efﬂux maintaining Ca2+ in the cell. GRKs regulate the
GPCR signaling, therefore the interplay between ion channels and
GPCRs, as well as the GRKs regulating them, is a critically important
mechanism of hypertension.
In hypertension, defective relaxation induced by ion channels
may be important to high blood pressure development. The hyper-
tensive phenotype of the spontaneously hypertensive rat (SHR) is
characterized by a down-regulation of the large-conductance Ca2+-
activated K+ channel (BKCa2+) [27], although other groups have
challenged this notion by showing increased presence of the BKCa2+ in
the vessel walls of SHHF rats [28]. Angiotensin induced hypertension
leads to decreased expression of the BKCa2+ channel and this was
attributed to a nuclear factor of activated T-cells (NFAT)/Calcineurin
dependent pathway [29,30]. Most recent data indicate that PKC
phosphorylation inhibits BKCa2+ channels in vascular smooth muscle,
whereas BKCa2+ channels are activated by vasodilators coupled to PKA
as shown in studies using β-adrenergic receptor agonists [31].
Regarding Ca2+ channels, expression has not been shown to
change in hypertension, but one study found increased blood pressure
to be the reason for elevated levels of pore forming subunit α1C
subunit in the vessels of SHHF rats [32]. Taken together these results
indicate that high blood pressure itself and the agonist activated
GPCRs underlying it may alter ion channel expression and activity,
thus constituting an input for blood pressure regulation. Whether
there is a role of GRKs on ion channel function remains to be deter-
mined but it is intriguing to hypothesize that GRKs may have some
direct effect.4. The role of GRKs in hypertension
Blood pressure is regulated by alterations in heart rate, vascular
resistance and ﬂuid and electrolyte balance, all of which are GPCR-
regulated and therefore largely subject to differential regulation by
GRKs.
4.1. GRK2
4.1.1. GRK2 synthesis and degradation
GRK mRNA levels are regulated in a variety of disease states and
during differentiation [33]. Vascular tone can act as a promoter of
aorta smooth muscle GRK2 expression in a Gαq dependent manner
[34]. Vasoconstriction led to enhanced GRK2-promotor activity
whereas dilatory stimuli and cytokines inhibited it. This effect was
cell-type speciﬁc as it could not be found in non-cardiovascular cell
lines such as epithelial (HEK293) cells [34]. Another group found that
activation of MAP Kinases (ERK1/2) increased endogenous GRK2
protein levels in primary cardiomyocyte cultures [35,36]. In cardio-
vascular disease, GRK2mRNA levels are upregulated [1] in correlation
with increased catecholamine levels and β-adrenergic receptor
activity [37], which suggests a reciprocal regulation that may explain
fundamental alterations of GPCR signaling in many pathophysiolog-
ical conditions.
Degradation of GRK2 occurs via the proteosome [33] in a process
depending on its own activity, as conﬁrmed by the slower degradation
of an enzymatic-activity-deﬁcient mutant (GRK2 K220). β-adrenergic
receptor stimulation accelerates the ubiquitination and degradation
of GRK2 in a feedback loop. Benovic et al. have found that heat-shock
protein Hsp90 has an important role in maturation of GRKs where
interaction between Hsp90 and GRKs may prevent GRKs from being
degraded by stabilizing the correct folding of the protein [38].
Furthermore, oxidative stress, which is often increased during disease
states, induces degradation of GRK2, at least in lymphocytes, possibly
via tyrosine phosphorylation [39]. These studies suggest that GRK2 is
intricately regulated at multiple levels through different signaling
events which makes it even more interesting to determine whether
changes in GRK levels concomitant with disease states are a cause or
consequence and the impact changes in expression of these kinases
have on GPCR signaling.
4.1.2. Upregulation of GRK2 in humans with hypertension and in animal
models of the disease
Evidence is accumulating to suggest a role of GRK2 in hyperten-
sion. GRK2 is increased in lymphocytes derived from young
hypertensive patients as well as in the VSM of animal models of
hypertension [40,41]. Increased GRK2 expression also correlated with
decreased activity of adenylyl cyclase downstream of isoproterenol-
stimulated β-adrenergic receptors [42]. We have recently described
in a larger cohort of black American adults that lymphocyte GRK2,
but not GRK5, mRNA expression and activity directly correlates
with systolic blood pressure [43]. Norepinephrine levels were also
increased in these subjects therefore, we proposed that a greater
sympathetic nervous system activation resulting in exaggerated
βAR signaling and subsequent GRK2-mediated desensitization of the
receptors may represent a potential mechanism. It also suggests
that GRK2 levels might be able to act as a surrogate measure of cate-
cholamine levels and catecholamine-mediated stimulation of GPCRs.
Other neurohormonal agonists are also regulated with increased
blood pressure and it is possible that these ligands, such as endothelin,
also elevated in hypertensive black Americans, contribute [44,45].
endothelin-A-receptors, predominantly mediating potent vasocon-
striction effects of endothelin-1 in VSM, were recently found to be
desensitized only by GRK2, and not GRK3, 5 or 6 [46]. These ﬁndings
would suggest a protective role of GRK2, preventing pro-hypertensive
signals from prevailing and pointing towards GRK2 elevation in
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complexity of signaling in that GRK2 may have inﬂuence over inputs
mediating either dilation and/or constriction and a need to further
understand the in vivo substrates for these kinases and the full
impact expression changes have on cardiovascular signaling. At
this point is should also be mentioned that there is a putative role for
the RH domain of the N-terminal region of GRK2 acting as a regula-
tor of G-protein function, namely as inhibitor of Gαq [47–49], in a
phosphorylation-independent manner, implying an additional
mechanism for GRK2-mediated inhibition of GPCR signaling to be
further investigated with respect to hypertensive disease.
Interestingly, when we created transgenic mice directing VSM
expression of GRK2 using a portion of the smooth muscle-speciﬁc
SM22α-promotor, the mice had elevated resting blood pressure with
subsequent vascular thickening and cardiac hypertrophy and exhib-
ited reduced sensitivity to vascular relaxation afforded by the β-
adrenergic receptor agonist isoproterenol [50]. Surprisingly, when
these animals were challenged with an agonist such as angiotensin II,
VSM GRK2 overexpression also reduced angiotensin II-mediated
constriction and blood pressure elevation. These ﬁndings suggest
that impaired β-adrenergic receptor signaling caused by desensitiza-
tion and subsequent decreased vasorelaxation is likely a primary
abnormality resulting from GRK2 overexpression in VSM. Why this
effect outranks the equally desensitized vasoconstricting GPCR-linked
signals such as angiotensin II warrants further investigation as do the
mechanisms underlying elevated GRK2 levels found in humans with
high blood pressure.
4.1.3. GRK2 regulates blood pressure by reducing nitric oxide production
in endothelial cells
Increased GRK2 expression may also play a role in hypertension
by reducing nitric oxide (NO) production [51,52] and thereby deacti-
vating one of the main vasodilatory response pathways in endothelial
cells. GPCRs critically regulate endothelial function and the mainte-
nance of vascular tone, but little is known as to the implications
of GRKs. GRK2 has, in an animal model of portal hypertension, been
shown to physically interact with Akt in endothelial cells, thereby
inhibiting the Akt-dependent activation of endothelial nitric oxide
synthetase (eNOS), and thus shift vascular tone towards constriction
[52]. In rats with portal hypertension, GRK2 expression was increased
and a restoration of Akt phosphorylation and eNOS activity as well
as a normalization of portal blood pressure could be afforded by
knock-down of GRK2 in vivo. Altered activity of adrenergic, angio-
tensin II and endothelin receptors all targeted by GRK2 might play an
important role in the critical function of the endothelium in the
pathophysiology of hypertension. This implies a beneﬁcial effective-
ness of similar drugs both in portal hypertension and heart fail-
ure. Therefore, it warrants further investigation to uncover the role
of GRKs in endothelial cells and their impact on blood pressure
regulation.
4.1.4. GRK2 overexpression in VSM leads to hypertension, vascular and
cardiac hypertrophy
The hypertensive state results in a dynamic process in the
structural aspects of blood vessels in an attempt to counterbalance
the increased pressure on the lumen wall by increasing vascular wall
thickness which thereby adds incrementally to narrowing of the
lumen.We found that VSM GRK2 overexpression led to a 30% increase
in vascular wall thickness. Further, we observed concomitant cardiac
hypertrophy [50]. Recent studies done by our group suggest that Gq
signaling may be implicated in this process and that they hypertrophy
may be directly dependent on the increased blood pressure because
inhibition of VSM Gq signaling normalized blood pressure and the
vascular and cardiac hypertrophy that was produced by overexpres-
sion of GRK2 [53].Further supporting our contention that the VSM-GRK2-mediated
cardiac and vascular hypertrophy was blood pressure driven,
mitogenic signaling and proliferation via endothelin-1, angiotensin
II, thrombin and platelet-derived growth factor were signiﬁcantly
reduced when GRK2 was overexpressed [54]. Further, a reduction of
neointimal hyperplasia in saphenous vein grafts through GRK2
overexpression in VSM cells was described suggesting that GRK2 in
and of itself, at least under certain conditions, is anti-hypertrophic
[55]. Whether this is the case remains to be further elucidated
but again, it speaks to the complexity of a few kinases regulating a
plethora of different GPCRs.
4.2. GRK3
GRK3 has a selectivity for the α1B-adrenergic receptor as well as
for the thrombin receptor that GRK2 does not exhibit [56] GRK3 has
been implicated in cardiac hypertrophy and a hypercontractile state
through regulation of the α1-adrenergic receptor. Inhibition of GRK3
expression in the cardiac myocardium caused hypertension, most
probably due to hypercontractility and increased cardiac output as a
result of hypersensitivity to activation of the α1-adrenergic receptor
[57]. Because α-adrenergic receptors are key regulators of vascular
resistance, GRK3 remains an intriguing target to further investigate.
4.3. GRK5/6
Unlike the classical desensitization procured by GRK2, phosphor-
ylation of GRK5 and GRK6 is now believed to also lead to recruitment
of non-classical signaling pathways [58,59]. GRK5/6 phosphorylation
is thought to facilitate arrestin-mediated transactivation of receptor
tyrosine kinases (RTKs) and subsequently activate PI3K and MAPK as
well as Ca2+ accumulation [60–62]. The implications of these ﬁndings
in regulation of contractile state of VSM through GRK5 remain to be
determined, but it has potentially profound implications in these cells.
GRK5 is upregulated subsequent to hemodynamic stress and
hypertension in animal models of angiotensin II and norepinephrine
induced high blood pressure [63]. This ﬁrst report determined that the
actual increase of sheer stress in vascular tissue was causing elevated
GRK5 levels, since continuous angiotensin II infusion in vivo at a
subpressor dose failed to elicit a response. In addition, pretreatment
with anti-hypertensive medications hydralazine or losartan were able
to abolish the effect suggesting it was increased blood pressure per se
that was increasing GRK5 expression. We also found that transgenic
overexpression of VSM-GRK5 using a portion of the SM22α-promotor
created transgenic mice that developed high blood pressure in a sex-
speciﬁc way, where the increase in mean arterial pressure was
approximately 45 mm Hg in male versus 17 mm Hg in female mice
[64]. Instead of the blood pressure being regulated by a decrease in β-
adrenergic receptor dilation, we found VSM-GRK5 induced hyperten-
sion was mediated by Gi signaling. Inhibition of Gi signaling using
pertussis toxin restored blood pressure to control values in both male
and female mice. Plasma catecholamine levels were comparable and
the lack of estrogen could not account for differences, since female
mice that had undergone ovariectomy did not show higher increases
in blood pressure, i.e. acquire the male phenotype. Furthermore,
vascular reactivity showed a differential pattern with female but not
malemice exhibiting exaggerated aortic constriction after angiotensin
II stimulation. The GPCR targets of GRK5 warrant further investigation
as the intricate mechanisms at play may provide helpful insight into
sex-speciﬁc efﬁcacy of anti-hypertensive therapy.
On a subcellular level, GRK5 in contrast to GRK2, has a DNA-
binding nuclear localization sequence and it has recently been
described that GRK5 in a model of pressure overload induced heart
failure trafﬁcs to the nucleus and is involved in the transcription of
pro-hypertrophic signaling via MEF-2 and HDAC5 [13]. These data
support an earlier study in spontaneously hypertensive heart failure
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hypertrophied myocardial tissue obviously due to hypertension,
suggesting a role in the regulation of hypertrophic gene transcription
[65]. The reverse did not seem to be true since in our study the
overexpression of VSM GRK5 leading to a hypertensive phenotype did
not create myocardial hypertrophy or heart failure [64]. On the whole,
our data suggest the involvement of GRK5 in development and
progression of hypertension may originate from a unique signaling
paradigm from GRK2, making its further study important to better
understanding potential causes and consequences of high blood
pressure.
5. RGS (regulator of G-protein signaling) proteins in hypertension
Parts of GRKs, namely the N-terminal portion, can act as an RGS,
and it has been shown that this can critically impact GPCR regulation
of vessel reactivity and blood pressure therefore, a discussion of this
family of proteins is included.
To date we have knowledge of about 35 RGS or RGS-like proteins
that were discovered as novel molecules governing the already
complex system of GPCR signal transduction and most are present in
the cardiovascular system [66]. RGS proteins – so called GTPase
activating proteins (GAPs) – negatively regulate GPCRs by accelerat-
ing Gα-dependent GTP hydrolysis to reconstitute the heterotrimeric
G-protein complex, thereby inhibiting the agonist induced dissocia-
tion of the Gα from the Gβγ subunit and preventing the activation
of downstream effectors [67]. RGS can also act by physically blocking
G-protein signaling by competing for a similar binding site. Three
members of the RGS protein family have been implicated in the
cardiovascular system, kidney and autonomous nervous system:
RGS2, RGS4 and RGS5. Data suggest that these three RGSs have
relevance in blood pressure maintenance in animal models as well as
in human disease [68]. It remains intriguing how GRKs interact with
or act as RGSs and this remains an important avenue of investigation.
5.1. RGS2
The RGS2−/− knock-out mouse is hypertensive and has altered
GPCR signaling in a number of tissues [69]. RGS2 has selectivity for
dampening Gαq signaling [70] both by regulating p63RhoGEF, an
activator of gene transcription, as well as GRK2-mediated GPCR
phosphorylation [71]. In vivo, it was not surprising that gene ablation
of RGS2 increased blood pressure, depending a signiﬁcant extent on
angiotensin II [72,73], [74]. As with most signaling molecules, upon
further investigation, the mechanism is more complex and it was
suggested that nitric oxide (NO)mediatedmechanisms act to increase
RGS2 activity and further enhance NO-mediated vasodilation [75,76].
Binding and phosphorylation of RGS2 by PKGI-α, a mediator of VSM
relaxation in response to NO, stimulates its GTPase activity and
further diminishes activation of Gq [77]. These ﬁndings further
promote the importance of RGSs as potential therapeutics because
they could potentially terminate maladaptive signaling through Gq-
coupled receptors. These features are possibly shared by GRKs
carrying an RGS homology, although this potential mechanism of
action remains to be elucidated.
5.2. RGS3
RGS3 proteins, a subfamily of RGS proteins, carry a characteristic
extended N-terminus, which is expressed in two truncated versions
that appear to be able to attenuate calcitonin gene-related peptide
(CGRP) receptor signaling through inhibition of both IP3 and cAMP
formation [78]. This suggests that RGS3 can regulate signaling through
both Gq and Gs thus if any of the GRKs had similar binding char-
acteristics to RGS3 they could work to further decrease GPCR
signaling. RGS3 can also bind to Gβγ and decrease MAPK, as well asPI3K activity [79]. Importantly, GRK2 associates with Gβγ through the
PH domain within its C-terminal portion. Whether it is also capable of
interacting with Gβγwithin its N-terminal RGS domain remains to be
determined. There is evidence for the RGS3-isoform RGS3L to act as a
molecular switch between Gβγ-mediated activation of Rac-1 and
RhoA [80] which, considering the importance of the ROCK pathway in
smooth muscle contractility, warrants further investigation with
respect to hypertension, even more, since RGS3 is has lately been
shown to be upregulated in human heart disease[81]. Recently,
another isoform of RGS3 was identiﬁed, PSD95 (postsynaptic density
95), which plays a role in protein assembly by way of its N-terminal
PDZ domain [82,83]. This is of relevance because PSD95 can also form
a complexwith the β1-adrenergic receptor, which can be disrupted by
GRK5 [84]. Interaction between GRK5, or any other GRK, and PSD95
remains to be determined. All of this taken together at least suggests
that if the GRKs do not act as RGS proteins per se, they could at least
affect RGS activity.5.3. RGS4
Although it was originally characterized as a brain-speciﬁc RGS,
the RGS4 isoform has been strongly implicated in regulation of
cardiovascular cell signaling, namely by interference with GPCRs
involved in myocyte function and hypertrophy, both closely linked to
vascular function and hypertension. RGS4 can likewise inhibit both
Gαq and Gαi-coupled signaling and was speciﬁcally shown to
interfere with endothelin-1 mediated effects in human heart disease
[85], but also is speciﬁcally upregulated in situations of pathophys-
iological stress, such as pressure induced hypertension and cardiac
hypertrophy in an animal model of suprarenal aortic banding [86]. In
this model, RGS4 was upregulated over 30 days and this effect could
not be blocked by AT1 receptor blockade. This implies a receptor
independent upregulation of RGS proteins in that model, which
importantly leads to impaired vascular reactivity to GPCR induced
contraction. It has also been shown that RGS4 in cardiac myocytes
inhibits phenylephrine and endothelin-induced myoﬁlament organi-
zation and cell growth [87,88], and associates with the muscarinic M2
receptor and G-protein coupled inward rectifying potassium (GIRK)
channels in atrial myocytes [89]. Whether GRKs interact with or act
similar to RGS4 remains to be determined.5.4. RGS5
RGS5 is expressed strongly and speciﬁcally in pericytes and VSM
[90]. In arterial VSM, RGS5 is able to activate GTPase and inhibits
angiotensin II and endothelin-induced intracellular Ca2+ transients
mediated by Gαi and Gαq [91–93]. MAPK activation pathway is also
regulated by RGS5 in VSM andMAPKwas increased after knock-down
of RGS5 in vitro, suggesting constitutive inhibition by endogenous
levels of RGS5 [94].6. RGS5−/− knockout leads to hypotension and lean body type
In contrast to the RGS2−/− mouse, mice lacking RGS5 exhibited a
phenotype with persistent low blood pressure [86,95]. This was
accompanied by dilated blood vessel diameter and unchanged vessel
wall thickness. Isolated aorta VSMs lacking RGS5 exhibited increased
extracellular signal-regulated kinase and vasodilator-stimulated
phosphoprotein activation [86]. The results suggest that RGS5 acts
by inhibiting nitric oxide-mediated dilatory signaling and thus would
act opposite to RGS2. Whether any of the GRKs have RGS5-like
binding domains and could either act similarly or compete with RGS5
remains to be determined.
1273H.L. Brinks, A.D. Eckhart / Biochimica et Biophysica Acta 1802 (2010) 1268–12757. Hypertension in development and progression of heart failure
In approximately 90% of patients, heart failure is preceded by
hypertension, according to the American Heart Association (AHA).
Hypertension remains a critical risk factor for pathological cardiac
hypertrophy, renal failure and stroke, diseases showing elevated RGK
levels and activities [15]. In a model of pressure overload hypertrophy
leading to heart failure, GRK-activity levels were 3-fold increased [96],
suggesting that GRK upregulation may play a role in the pathophys-
iological basis of hypertensive heart failure. In an earlier study by our
group using spontaneously hypertensive heart failure (SHHF) rats, the
decline of β-adrenergic responsiveness was in fact preceded by an
earlier increase in GRK2 levels [97]. This indicates that upregulation of
GRK2 may be a potential target in the prevention of hypertensive
heart disease to heart failure (Table 1). Whether changes in cardiac
GRK levels are due to hypertension itself or a result of increased
neurohormonal activation that is associated with high blood pressure
remains to be determined.
8. GRK2 inhibition in VSM as a potential therapeutic target
The delicate balance between relaxation and constriction is
swayed towards constriction by impaired vasodilation due to
alteration in β-adrenergic receptor signaling. The important role of
β-adrenergic receptor mediated vasodilatory effects is critical for
blood pressuremaintenance and the resensitization of these receptors
is a potential therapeutic path. Development of a GRK2 inhibitor,
comprised of the last 194 amino acids of the C-terminal end of GRK2,
has given us a tool to selectively block desensitization of GRK2-
sensitive GPCRs. This molecule has been termed βARKct or GRK2ct
(GRK2 was originally named β-adrenergic receptor kinase — βARK1)
and it has been shown to have diverse effects. Koch et al. have found
that cardiac-speciﬁc overexpression of the βARKct increased cardiac
contractility through enhanced β-adrenergic signaling and preventedTable 1
Summary of studies elucidating the implications of GPCR-mediated blood pressure
regulation being altered by GRKs and RGSs.
Regulator Function in blood pressure regulation Reference
GRK2 GRK2 is increased in lymphocytes in
Hypertension
Gros (1997);
Gros (2000)
Increased GRK2 in VSM causes elevated
blood pressure and lead to increased
vascular wall thickness
Eckhart (2002)
GRK2 reduces NO production in endothelial
cells
Liu (2005)
GRK2 regulates Endothelin-1-mediated
vasoconstriction
Morris (2009)
Increased GRK2 levels correlate with high
blood pressure
Cohn (2009)
GRK5 GRK5 upregulation in response to elevated
blood pressure
Ishizaka (1997)
VSM-overexpression of GRK5 leads to
gender speciﬁc high blood pressure
and vascular hypercontractility
Keys (2005)
RGS2 Lack of RGS2 produces a spontaneous
hypertension and are more sensitive
to induced hypertension
Heximer (2003)
Hercule (2007)
RGS2 phosphorylation by PKGIα diminishes
Gq activity
Tang (2003)
RGS2 polymorphisms are associated
with hypertension and obesity
Riddle (2006),
Kohara, (2008)
Sartori (2008)
RGS5 RGS5 knockout leads to hypotension
and lean habitus
Cho (2008)
Nisancioglu (2008)
Tumors lacking RGS5 are more susceptible
to therapy
Hamzah (2008)
Decreased RGS5 in VSM of artherosclerotic
lesions
Li (2004)the progression of heart failure in animal models of the disease
[13,98]. Viral vector-mediated gene delivery of this peptide to
myocardium led to marked improvement of cardiac function in a
model of ischemic heart disease [99]. Given the recent push for novel
gene therapy development through successful clinical application for
instance in ophthalmology and cancer therapy, and ﬁrst clinical
application of genes therapeutic in heart failure [100], we expect this
ﬁeld to develop rapidly and look forward to applications relevant in
hypertension.9. Conclusion
The etiology of hypertension remains elusive. It is a complex and
multifactorial disease and as such is unlikely to be successfully treated
with a singular approach. Current standard therapy includes inhibi-
tion of angiotensin II AT1 receptors as well as enhancement of nitric
oxide-mediated relaxation of VSM. Further, β-adrenergic receptors
are also blocked and the mechanisms of action are thought to be
through cardiac effects. It appears that the majority of GPCRs are
regulated by GRKs suggesting that, in multifactorial diseases such as
hypertension, GRKs might represent valuable targets for novel
therapeutic approaches since they act in a more generalized fashion
on the intracellular mediators of GPCRs rather than just blocking one
selective agonist from exerting its action. To overcome the imbalance
of arterial relaxation and contraction we will have to outsmart the
intricate mechanisms within vascular tissues. GPCR regulation offers
a broad and potent base for further study and development of ther-
apeutic options to overcome a devastating disease.Acknowledgements
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